What is on the table for the next Standing Committee on Copyright and Related Rights: Twenty-Seventh Session (SCCR/27) April 28 to May 2, 2014 (Geneva, Switzerland)?
On April 1, 2014, ViiV, a consortium of Pfizer and GSK, and the Medicines Patent Pool (MPP), announced two new licensing agreements that expand generic competition for dolutegravir (DTG), and integrase inhibitor used for the treatment of adult and pediatric HIV infection. (MPP press release here.) Dolutegravir is a new drug, approved for marketing by the US FDA on August 12, 2013. Continue Reading